1 / 32

Wanbury Limited

Wanbury Limited. February 2006. Disclaimer.

tyme
Download Presentation

Wanbury Limited

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Wanbury Limited February 2006

  2. Disclaimer This presentation is made purely for information. We have tried to give relevant information which we believe will help in understanding the Company. The viewers may use their own judgement and are advised to make their own calculations before deciding on any matter based on the information given herein. While every care is taken to verify the accuracy of the information given in this presentation, neither the Company nor its officials would in any way be liable for any action taken or not taken by the viewers or the users of this presentation or for any claims, losses etc. This is not a prospectus or document soliciting investment in the Company

  3. Overview

  4. Our Vision … To become a global pharmaceutical company with presence in Formulations and APIs …. … a market capitalisation in excess of Rs.1000 cr ……by March 2009

  5. Business Model BULK BUSINESS DOMESTIC FORMULATIONS FORMULATIONS OVERSEAS

  6. Bulk Business

  7. Snapshot • World’s largest producer of Metformin • We sell to leading global generic players in regulated markets • Exporting to over 50 countries • Over 14 products ... Of these over 8 products for US and Europe • 3 API facilities with 2 USFDA approved for multi product in Maharashtra and AP • Over 24 products within 18 months and foray in contract manufacturing • Aggressive pitch of DMF Filings through a strengthened Research Base. New R&D centre set up at Navi Mumbai for Process Research

  8. Apotex, Canada Torr Pharma, USA Mylan, USA Barr Laboratories, USA TEVA, Israel Dexxon, Israel Pliva, USA Remedica, Cyprus Drageno Pharma, Germany Moleculus Mexico Pfizer Mega Pharma, Mexico Pure Pharma, Europe Salutos, Germany Wessex, UK Tabuk, Saudi Arabia Pharmire, Sourth Korea Ranbaxy, India Strides Arcolabs Glenmark,India Sun Pharma, India Cadila Pharmaceuticals Alkem, India Key Customers

  9. Product Portfolio • Gabapentene Int. • Tramadol • Amitryiptyline Promethazine • Metformin • Salsalate • Ibuprofen • Glucosamine • Mefenamic Acid • Meloxicam • Fluvastatin • Glybenclamide • Gabapentene • Clopidogrel Existing • Sertraline • Paroxetine Hemihydrate • Carvedilol • Desloratidine • Losartan Potassium Introductions this year • Gliclazide • Pantaprazole • Fluconazole • Hydrochlorthyzide Pipeline for 2007 ….a market size of over $ 2 Bn

  10. Product Pipeline DMFs Available DMFs in Process Scale up Lab Stage New Products Losartan Potassium Carvedilol Clopidogrel Hydrogen sulphate Carvedilol Diphenhydramine Hydrochloride Glucosamine Sulfate Kcl Glucosamine Sulfate NaCl Pantaprazole Methoxsalen Irbesartan Meloxicam Fluvastatin Glybenclamide Gliclazide Fluconazole Venlafaxine Metformin HCl Tramadol Hydrochloride (EDQM) Tramadol Hydrochloride( US) Promethazine Hydrochloride Sertraline Hydrochloride Amitriptyline Hydrochloride Paroxetine Hydrochloride Metformin HCl DC grade 90% Metformin HCl DC grade 95% Ibuprofen DC grade 90% Glucosamine HCl Ibuprofen Mefenamic acid Ondansetron Risperidone Venlafaxine Glimepiride

  11. Our Research Strategy Process Research Pharma Research NDDS Development of novel platforms for Specialty Generics and IPR APIs for Regulated markets /Emerging markets and Contract manufacturing Development of ANDAs and finished dosages for regulated markets

  12. Our Research Strategy

  13. Stage I- Process Research Center • Area of Focus • Widening DMF pipeline for regulated markets (10 DMFs over 15 m) • New Product introductions for emerging markets • Intermediate manufacturing for innovators • Development for Contract Manufacturing • Widened coverage of therapeutic area • _ Custom synthesis • Research Set-up • Existing facilities to be strengthened and new Research Facility being set up in Navi Mumbai • Team comprising 20 scientists with 4 PhDs in Organic Chemistry • Well equipped analytical Lab comprising HPLCs, GCs, FTIR, UV Visible, Particle size analyser etc • Team expandable to 60 scientists over 24 months

  14. Stage II Research Center • Area of Focus • Development of Formulations • Dossier preparations and ANDA filings for regulated markets • Development of platforms for Novel Drug Delivery for Speciality Generics • Clinical Research Capabilities for carrying out bio equivalence studies • Research Set-up • New facility for a closed loop research lab to be set up close to Mumbai/Pune • Full service Analytical Lab with NMR, HPLCs, GCs, FTIRs, ,XRD,DSC,GCMS,LCMS. • Lab Management Systems • Clinical Research capabilities starting with capabilities for bio equivalence studies • Facilities for In vivo studies • Animal House for In vitro studies

  15. Contract Manufacturing • Wanbury is well positioned to emerge as an outsourcing partner of choice due to our quest for quality, desire for innovation, a highly efficient supply chain management and optimal utilization of capacities. • Wanbury is in an unique position to offer a single point of contract for R&D, process development and production. Availability of dedicated, adequately trained and highly qualified manpower in R&D , production and QA/RA.

  16. Custom Synthesis • Custom synthesis • Already carrying out synthesis for European customers • Expanding team of scientific officers to procure business • New systems to be incorporated in the R&D to strengthen IPR protection and facilitate business

  17. Reaction Capabilities • In addition to general reactions we are specialised in the following • Azidation • Bromination • Reactions involving Butyl Lithium • Cyanation • Chiral chemistry • Griganard • Sodium metal reactions • Metal hydride reductions • Optical Resolution • High Pressure Reactions • Hydrogenation • High Temperature Reactions (250°C) • High Vacuum Distillations • Low Temperature Reactions (-80°C)

  18. Formulation Business

  19. Our Formulation Business • Founded in 1865 by Dr. George Wander in Berne, Switzerland • Wander has been in the Indian market since late forties with it’s cold and nutrition products …originally a subsidiary of Sandoz • Now a Wanbury division with 310 professionals, 16 brands, 24 Distributors and about 1200 stockists across the country. • Independent Formulation Research and Development Centre at Chembur recognised by Govt. of India • Strong focus on Pediatrics, Gynecology and Orthopedics • Growth through niche neutraceuticals led lifestyle segment

  20. Brands Doctor Segment Brands C-Pink Coriminic Zeva Nurture SetCal Gemron Cemax-O Cefcare Oftek Ofgyl Nock -2 Adtrol Clamist Senasof Pediatrics Gynecologists Orthopedics Consulting Physicians GPs

  21. Growth Strategy

  22. Growth Strategy • Existing Satisfied Customers • Strong Marketing Skills • In-house technical competence • In-house Research expertise • Experience in managing and building US FDA approved plants LEVERAGE ON …. Global Generics Contract Manufacturing Strategic Alliance Product Introductions Life Style Division Acquisitions Expansion Improve PCPM 4 Years

  23. Management

  24. Board of Directors • Mr. K Chandran ..ED • Mr. K.R.N. Moorthy ..ED • Mr. N. K. Puri ..Independent • Dr. P. L. Tiwari ..Independent • Mr. A. Bongirwar ..Independent • Mr. S. Bhattacharya ..Nominee(EXIM)

  25. Advisory Board • Mr. K. R. N. Moorthy is supported by an advisory board: • Mr. S. Balsekhar, • Ex-Chairman Roussel Pharmaceutical • Dr. Indira Parekh, • Dean IIM Ahmedabad • Group Directors

  26. Human Resources

  27. Key Personnel BOARD of DIRECTORS ADVISORY BOARD K R N MOORTHY ED & President APIs/Formulations ASHOK SHINKAR Director C F (M&A) S R Jagannathan Sr. VP Operations Dr S Samant V P Marketing S Jayaram V P Legal M.K. PADMANABHAN National Sales Manager P. Gupta Company Sec. Dr. Pulla Rao Head QA and Regulatory Vijayan Nair GM Finance V S Ayare R&D Mahesh Kolatkar AGM IT Raman Iyer GM Marketing Kurush Dubash Head Training Dr Shankar GM R&D Surina Iyer DGM HR

  28. Management – Key personnel

  29. HR Thrust .. Focus Areas • Talent Acquisition – Selection Techniques • Team Alignment & Rationalization • Measuring Performance & Assessing Potential • Compensation Benchmarking • Capability Building and Leadership Development • Career Development & Succession Planning • Create Think Tank ~ Innovative Practices • Communication – Openness – Transparency - Speed • System Orientation Building Human Capital ….. For Superior & Competitive Results

  30. Wanbury’s VALUES • Respect for People • Innovation • Sense of Urgency • Result Focus • Leadership • Team Work • Customer Focus

  31. Mission statement We at Wanbury, want to make a company that employees are proud of and committed to, where every employee has an opportunity to contribute, learn, grow and advance on merit. We are dedicated in improving quality of our employees by continuously providing high quality training and development. We will continue to establish a business model, which is predictable, sustainable, growth oriented and profitable. We will always worship exceptional and superior performance. We will continuously challenge status-quo / maintenance and simultaneously encourage and recognize stretch and growth. We will work hard not only to satisfy but delight our customers (both internal and external). We will strive to make Wanbury one of the preferred employers.

  32. Thank You

More Related